RCS - Verici Dx PLC - CAP accreditation

Verici DxAnnouncement

08/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240108:nRSH8696Ya&default-theme=true

RNS Number : 8696Y  Verici Dx PLC  08 January 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Verici Dx Clinical Laboratory achieves CAP accreditation

 

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ
transplant, announces that its testing laboratory in Franklin, TN, has been
accredited by the internationally recognised College of American Pathology
(CAP) following the completion of an on-site audit. The Company, whose
clinical laboratory is already CLIA certified, voluntarily sought the
accreditation as part of its on-going commitment to maintaining best in class
quality systems.

 

CAP accreditation is a hallmark of quality and excellence in clinical
laboratory services and adds to the Company's existing portfolio of quality
assurance awards and recognition.

 

In achieving the CAP accreditation requirements, which often exceed the
standards from CLIA, FDA and OSHA, Verici Dx exhibits focus on excellence in
patient care and laboratory safety. It also further demonstrates the
laboratory's ability to deliver reliable and accurate test results to support
patient clinical management.

Patti Connolly, Chief Operating Officer at Verici Dx, said: "We are pleased
that our highly skilled laboratory team successfully achieved this
accreditation with no deficiencies, findings, or recommendations identified
during the audit. This accomplishment affirms our commitment to operating at
the highest standards that healthcare providers, patients, and regulatory
bodies expect."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Sam Butcher / Jalini Kalaravy

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Stephanie Cuthbert / Sam Allen                           Mob: 07796 794 663 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRMBTMTIMTTI